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To the Editor
Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of tumor B-cells within the blood and tissues
[1]. Patients with unmutated (U-CLL) or mutated (M-CLL)
IGHV genes typically have a progressive or indolent disease,
respectively. However, B-cell receptor (BCR) signaling adds
a further complexity and is pivotal to CLL pathogenesis,
promoting tumor survival, proliferation, and consequently
tumor progression [2]. Indeed, inhibition of this pathway has
revolutionized clinical responses in patients [3].
Macroautophagy (herein Autophagy) maintains cellular
homeostasis through bulk protein degradation. During the
autophagy process LC3 (microtubule associated protein 1
light chain 3) and GABARAP (GABA type A receptor
proteins) family proteins, ATG3 and ATG7 are essential for
autophagosome formation, autophagosome–lysosome
fusion, and cargo degradation (Supplementary Fig. S1) [4].
In CLL, high basal expression of autophagy genes, BECN1,
PIK3C3, and PIK3R4, have been associated with a shorter
time-to-ﬁrst treatment (TTFT) and worse overall survival in
patients [5]. Furthermore, BECN1 and ATG5 RNA
expression have been shown to correlate with poorer clinical
outcome [6] and autophagy was shown to reduce therapy-
induced apoptosis [7]. However, how BCR activation reg-
ulates autophagy in CLL has not been previously evaluated.
Evaluation of basal autophagy-protein levels demon-
strated signiﬁcantly greater LC3B-II, GABARAPL2,
ATG3, and ATG7 in CLL cases (Supplementary Table S1;
for antibody information, see Supplementary Table S2)
compared with healthy donor B-cells (HDB) (Fig. 1a and
Supplementary Fig. S2A). The basal levels of LC3B-II, but
not GABARAPL2, ATG3, or ATG7, were signiﬁcantly
greater still in U-CLL compared with M-CLL (Fig. 1b and
Supplementary Fig. S2B). In addition, LC3B-II and ATG3
levels, but not GABARAPL2 or ATG7, associated with
BCR signaling capacity (Fig. 1c and Supplementary
Fig. S2C). With signiﬁcantly greater levels of LC3B-II and
ATG3 observed within U-CLL compared with MCLL-LS
due to the contrasting extremes of anti-IgM-mediated sig-
naling between these two subgroups. M-CLL-S samples
that retained anti-IgM signaling capacity expressed LC3B-II
at an intermediate level between U-CLL and M-CLL-LS
cases (Fig. 1c), suggesting LC3B-II levels were inﬂuenced
by both inherent BCR signaling and the cells’ origin.
Indeed, greater LC3B-II levels were associated with a
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signiﬁcantly shorter TTFT from the ﬁrst lymphocytosis
(Supplementary Fig. S3A) irrespective of IGHV mutational
status, as both cohorts expressed a mixture of U-CLL and
M-CLL cases. Intriguingly, although numbers were small,
LC3B-II expression also appeared to identify M-CLL
patients, but not U-CLL patients, which required earlier
treatment (Supplementary Fig. S3B). However, further
work in a larger trial using a fully quantitative technique is
required to identify the potential of LC3B-II as a biomarker.
To determine whether autophagy occurred in vivo, we
performed immunohistochemistry on lymph node tissue
from CLL patients and control tissue from healthy, reactive
nodes. LC3B expression was detected most strongly within
proliferation centers from sequential tissue sections labeled
with Ki67 (Supplementary Fig. S4A, B) and in reactive
node germinal centers (Supplementary Fig. S4D). This
shows that LC3B expression is associated with CLL cells
and B-cells that had undergone antigen engagement. These
cells appeared to be B-cells given that the majority of cells
were CD20+ in sequential tissue sections (Supplementary
Fig. S4C, D).
Consequently, we assessed whether BCR engagement for
2, 4, or 24 h with bead-bound anti-IgM or anti-IgD could
modify expression of key autophagy proteins LC3B-II,
GABARAPL2, ATG3, and ATG7 in CLL cells (Fig. 1d and
Supplementary Fig. S5A, B). Signiﬁcant increases in the
level of all proteins were observed 24 h following treatment
with anti-IgM. However, signiﬁcant increases in GABAR-
APL2 and LC3B-II also occurred earlier between 2 and 4 h,
whereas ATG3 and ATG7 only demonstrated trends for
increased expression at this time. Subsequent evaluation of
LC3B-II expression in a larger cohort of patients treated with
bead-bound anti-IgM for 24 h demonstrated that the majority
of CLL cases activated their autophagy pathway in response
to BCR engagement (Supplementary Fig. S5C). Further-
more, U-CLL cases expressed greater levels of LC3B-II in
response to anti-IgM compared with M-CLL cases (median
fold increase of 5.4 and 3.5, respectively; Fig. 1e). Some
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Fig. 1 Characterization of autophagy-marker protein levels at baseline
and following BCR engagement. a Protein was extracted from snap-
frozen PBMCs isolated from CLL patients or HDB puriﬁed by
negative selection. The level of LC3B-II (n= 43), GABARAPL2 (n=
19), ATG3 (n= 42), and ATG7 (n= 40) was quantiﬁed by immu-
noblotting and normalized protein levels relative to the Hsc70 loading
control are shown. Mean values are indicated. A Mann–Whitney test
was used for statistical analysis. b Basal LC3B-II protein levels in
CLL samples (n= 43) divided by IGHV mutational status into mutated
(M-CLL) and unmutated (U-CLL) cases, and (c) BCR signaling
capacity deﬁned by U-CLL, M-CLL signallers (M-CLL-S) (>5%
iCa2+ ﬂux), and M-CLL low signallers (M-CLL-LS) (≤5% iCa2+ ﬂux).
Mean values are indicated. A Mann–Whitney test was used for sta-
tistical analysis. d CLL samples were treated with bead-bound isotype
control antibody (IC), anti-IgM, or anti-IgD for 2, 4, or 24 h, and the
level of LC3B-II (n= 21) assessed by immunoblotting. Blots were
quantiﬁed and the mean fold change (±SEM) in the level of LC3B-II
with anti-IgM normalized to the IC at 2 h is shown. A Wilcoxon’s
matched-pairs signed-rank test was used for statistical analysis. e A
larger cohort of patient samples (n= 45) were treated with bead-bound
anti-IgM for 24 h and LC3B-II levels divided according to IGHV status
into M-CLL and U-CLL as previously described. Mean values are
indicated. A Mann–Whitney test was used for statistical analysis
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overlap in the anti-IgM-mediated LC3B-II levels was iden-
tiﬁed between IGHV subsets that maybe a result of M-CLL
cases with active BCR signaling. Compared with anti-IgM,
anti-IgD-induced signaling is short-lived in CLL cases [8].
Therefore, although signiﬁcant increases in LC3B-II were
observed following bead-bound anti-IgD treatment at all time
points, with trends for increased GABARAPL2, in most
instances these increases were smaller than that observed
with anti-IgM (Supplementary Fig. S5D). Similarly, a small
but signiﬁcant increase in ATG7 levels were observed at 24 h
with bead-bound anti-IgD, with only a trend for increased
ATG3 expression at 24 h (Supplementary Fig. S5D).
We subsequently characterized the signaling pathways
involved in BCR-mediated autophagy (Supplementary
Fig. S6). Phospho-ERK and -AKT levels increased 15 min
post stimulation with bead-bound anti-IgM or anti-IgD,
which is indicative of active BCR signaling. Interestingly,
anti-IgM and anti-IgD increased phospho-p70 S6 kinase
levels at 6 h, indicating active mammalian target of rapa-
mycin signaling, despite an induction of LC3B-II expres-
sion, suggesting activation of non-canonical autophagy [9].
At 24 h, anti-IgM- and anti-IgD-dependent increases in
LC3B-II, p62, and phospho-ATG13 suggested simulta-
neous activation of canonical and non-canonical autophagy
[9, 10].
Next, we assessed autophagosome formation using
LC3B puncta formation by immunoﬂuorescence [11]. Basal
autophagy was observed in cells treated with bead-bound
control antibody (Supplementary Fig. S7A, B), whereas
treatment with bead-bound anti-IgM increased LC3B
puncta to levels above that seen in the control (Supple-
mentary Fig. S7A, B).
To conﬁrm that bead-bound anti-IgM-mediated autop-
hagy was BCR-mediated and not a bead-dependent affect,
CLL cells were treated with bead-bound or soluble anti-IgM
in the presence or absence of the autophagosome inhibitor
hydroxychloroquine (HCQ). Both soluble and bead-bound
anti-IgM signiﬁcantly increased LC3B-II and GABAR-
APL2 levels compared with the control (Supplementary
Fig. S8A, B), conﬁrming that the induction of autophagy
proteins was mediated by BCR engagement and was not a
bead-dependent effect. Treatment with soluble anti-IgM
resulted in smaller autophagy protein increases in the same
CLL samples compared with bead-bound anti-IgM, likely
due to the relatively higher BCR signal strength and dura-
tion with bead-bound verse soluble anti-IgM [12].
To determine whether the anti-Ig-dependent regulation of
autophagy was B-cell or tumor speciﬁc, we treated HDB
with bead-bound or soluble anti-IgM or anti-IgD for 24 h.
Bead-bound anti-IgM, and to a lesser extent anti-IgD, pro-
moted signiﬁcant increases in LC3B-II levels (Supplemen-
tary Fig. S9A, B), suggesting that this phenomenon was B-
cell and not tumor-speciﬁc. However, in contrast to CLL,
these changes were not consistently replicated in the other
autophagy markers examined.
To determine whether BCR engagement blocked LC3B-
II degradation or induced autophagosome formation, we
assessed autophagic ﬂux in response to bead-bound anti-
IgM using immunoblotting in the presence or absence of
HCQ as described in the autophagy guidelines [11]. CLL
cells treated with HCQ accumulated LC3B-II in a
concentration-dependent manner, which was further aug-
mented with bead-bound anti-IgM (Fig. 2a). The LC3B-II
increases were not a result of HCQ-mediated effects on
BCR signaling (Supplementary Fig. S10) and also occurred
in a time-dependent manner at the RNA level (Supple-
mentary Fig. S11A). Comparatively, bead-bound anti-IgD
stimulation produced similar but much smaller responses
than anti-IgM (Supplementary Fig. S11B). These data
conﬁrm that BCR engagement does not block autosomal
degradation but induces the expression of autophagy-
associated genes leading to increased autophagic ﬂux.
Next, we used interleukin (IL)-4 and BCR kinase inhi-
bitors to conﬁrm the role of BCR signaling in the regulation
of BCR-mediated autophagy in CLL. We previously
demonstrated that IL-4 induced surface IgM (sIgM)
expression and subsequent downstream signaling [13]. IL-4
treatment signiﬁcantly increased sIgM expression as pre-
viously demonstrated and augmented anti-IgM-dependent
LC3B-II levels (Fig. 2b and Supplementary Fig. S12A, B).
These affects appeared to be BCR-mediated, as IL-4 had no
substantive effect on LC3B-II levels alone, even in the
presence of HCQ. Next, we inhibited BCR signaling with
tamatinib (SYK) and Ibrutinib (BTK), and observed the
effect on LC3B-II levels. Both inhibitors signiﬁcantly
reduced LC3B-II to basal levels (Fig. 2c and Supplementary
Fig. S12C). These data conﬁrm the role of BCR signaling in
the regulation of autophagy in CLL.
Previous studies have shown a role for autophagy in
resistance to venetoclax-mediated killing in follicular lym-
phoma [14]. Therefore, we hypothesized that autophagy
inhibitors may synergize with established therapies to
inhibit basal, BCR-induced, or therapy-induced autophagy
in CLL. To address this, we examined the effect on CLL
cell viability of combining the autophagy inhibitor, VPS34-
IN1, with venetoclax following bead-bound anti-IgM
treatment. We observed signiﬁcant synergy between
VPS34-IN1 and venetoclax compared with single-agent
treatment (Fig. 2d, e). Importantly, VPS34-IN1 inhibited
BCR-mediated LC3B-II increases but had no effect on BCR
signaling (Supplementary Fig. S13A, B), and both ABT-
199 and VPS34-IN1-mediated cell death was largely
caspase-dependent (Fig. 2d). These data indicate a protec-
tive cellular effect of BCR-mediated autophagy in CLL and
highlight the therapeutic potential of inhibiting autophagy
pathways to promote greater CLL cell killing.
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Fig. 2 BCR-mediated autophagy is dependent on BCR signaling and
provides a survival advantage to CLL cells. a CLL samples (n= 11)
were treated with bead-bound isotype control antibody (IC) or anti-
IgM with or without HCQ at indicated concentrations for 24 h and
LC3B-II levels evaluated by immunoblotting. A representative
immunoblot is shown. Blots were quantiﬁed and the mean fold change
(±SEM) in LC3B-II level with each treatment vs. IC without HCQ is
shown in the accompanying graph. A t-test was used for statistical
analysis. b CLL samples (n= 6) were treated with or without IL-4 (10
ng/ml), in the presence or absence of HCQ, for 24 h before treatment
with bead-bound IC or anti-IgM for 24 h. LC3B-II levels were eval-
uated by immunoblotting and the mean fold change (±SEM) in LC3B-
II levels with each treatment vs. IC without HCQ is shown. A Wil-
coxon’s matched-pairs signed-rank test was used for statistical ana-
lysis. c CLL samples (n= 10) were treated with HCQ and a SYK
(tamatinib; Tam) or BTK (ibrutinib; Ibr) inhibitor (both 5 μM) for 1 h
before stimulation with bead-bound IC or anti-IgM for 24 h and the
LC3B-II level evaluated by immunoblotting. Hsc70 was used as a
loading control. A representative immunoblot is shown. Blots were
quantiﬁed and the mean fold change (±SEM) in LC3B-II level with
each treatment vs. IC DMSO is shown in the accompanying graph. A
Wilcoxon’s matched-pairs signed-rank test was used for statistical
analysis. d CLL samples were treated for 6 h with bead-bound IC
or anti-IgM before treatment with autophagy inhibitor, VPS34-IN1
(3 μM), either alone or in combination with venetoclax (5 nM n= 6, or
10 nM n= 8 where shown) for 24 h. All conditions were carried out
with or without Q-VD-Ph (10 μM) to identify caspase-dependent drug-
mediated cell killing. Cell viability was assessed by the CellTiter-Glo
Cell Viability Assay. The mean (+SEM) percentage of viable cells
relative to IC is shown. A Wilcoxon’s matched-pairs signed-rank test
was used for statistical analysis. e Synergy between VPS34-IN1
(3 μM) and venetoclax (5 nm, left and 10 nM, right) was evaluated as
detailed in the Supplementary Materials and Methods. XY line,
observed survival= expected survival. Points below the line, syner-
gistic interactions; points above the line, additive interactions
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